03:07 , Jun 7, 2019 |  BC Innovations  |  Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
13:09 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies identified a CDK7/CDK12/CDK13 inhibitor that could help treat ovarian cancer. Screening of 42 small molecules targeting transcriptional and/or epigenetic components in two human ovarian cancer cell lines...
16:13 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer In vitro and cell culture studies identified a dual CDK12/CDK13 inhibitor that could help treat breast cancer. Screening of a small molecule library and in vitro enzyme activity assays followed by structure-based...
15:22 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and cell culture studies suggest inhibiting BARD1, BRCA1, CDK1 or CKD12 could help treat tamoxifen-resistant breast cancer. In tumor tissue from 27 recurrent breast cancer patients whose tumors became resistant...
23:37 , Dec 21, 2017 |  BC Extra  |  Preclinical News

New pathway could overcome resistance to TKIs in cancer

In a paper published in Cancer Research , researchers at Dana-Farber Cancer Institute and colleagues discovered that the recently identified ufmylation pathway plays a role in resistance to tyrosine kinase inhibitors (TKIs), and suggested that...
07:00 , Apr 14, 2016 |  BC Innovations  |  Product R&D

AACR by the numbers

See Figure: Top indications See Table: Novel cancer targets at AACR 2016 See Figure: Top institutions and companies See Figure: Top targets Tables Novel cancer targets at AACR 2016 Breast cancer amplified sequence 1 (BCAS1)...
07:00 , Jul 24, 2014 |  BC Innovations  |  Targets & Mechanisms

Selecting CDK7

Selective inhibitors of cyclin dependent kinase s have been hard to develop because the active sites of many family members are so similar. Now, a Harvard Medical School team has found a cyclin dependent kinase...
08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Cyclin-dependent kinase 12 (CDK12) loss-of-function mutations as predictors of poly(ADP-ribose) polymerase (PARP) inhibitor response In vitro and mouse studies suggest CDK12 mutations could help predict tumor...